

Zoetis Inc. (ZTS)

NYSE; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001555280

Zoetis Inc. ZTS; healthcare	
Grade	B A B C D E second fifth of 371 graded peers percentile 25.4; sampling error 2.5 points; lower is stronger
Rank	95 of 371
Profitability	B/C percentile 37.9
Solvency	C percentile 45.0
Growth and financing	B/C percentile 38.5
Reliability	0.94 AUC filers with over \$2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025
Peer failure rate	0.52% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	over \$2.67B assets total assets \$15.5B
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	none active not computable: fortress balance sheet
Inputs computable	9 of 14
Graded from	filings received through Feb 12, 2026 239 days before the rescans; latest periodic filing 10-Q received Aug 6, 2026
Last close	\$73.10 2026-10-08; market equity \$30.2B
Price used in grade	None



B, the elk

second fifth of its sector; letters are fifths of the 371 graded peers

Share price, twelve months to the rescans


split-adjusted close; the letter is fixed at the rescans that set it



Rescans on file: C from Feb 21, 2025, B from Feb 21, 2026, B/C from Mar 21, 2026, B from Aug 21, 2026

Letter at every rescanscan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Feb 12, 2026

In order to sell our products, we must be able to produce and ship our products in sufficient quantities. Many of our products involve complex manufacturing processes and are sole-sourced from certain manufacturing sites. Minor deviations in our manufacturing or logistical processes, such as temperature excursions or improper package sealing, could result in delays, inventory shortages, unanticipated costs, product recalls, product liability and/or regulatory action. In addition, a number of factors could cause production

interruptions that could result in launch delays, inventory shortages, recalls, unanticipated costs or issues with our supply agreements with third parties.


The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 37.9						
Gross profitability		44.0%	32.2%	27.8	372	2025-12-31
Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		(1.6%)	(6.6%)	77.7	811	2025-12-31
Gross margin stability, five years		0.7 pts	2.8 pts	8.3	243	2025-12-31
Solvency, sleeve percentile 45.0						
Twelve-month failure probability		0.05%	0.07%	34.4	248	2026-06-30
Altman Z double-prime		not computable	(0.31)			one or more required annual facts are missing
Net debt to EBITDA		not computable	1.82x			one or more required annual facts are missing
Interest coverage		not computable	(4.51x)			one or more required annual facts are missing
Current ratio		3.03x	2.96x	55.6	839	2025-12-31
Growth and financing, sleeve percentile 38.5						
Revenue growth, three-year compound		5.4%	10.0%	58.5	415	2025-12-31
Free cash flow growth, three-year compound		19.9%	10.9%	44.2	96	2025-12-31
Reinvestment rate		not computable	37.1%			one or more required annual facts are missing
Asset growth, three years		1.2%	2.1%	48.8	704	2025-12-31
Net share issuance, one year		(5.7%)	2.5%	2.7	634	2026-02-06

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
90	Sarepta Therapeutics, Inc. (SRPT)	24.1	B	
91	Pulmonx Corp. (LUNG)	24.3	B	fortress balance sheet

92	Amphastar Pharmaceuticals, Inc. (AMPH)	24.6	B
93	Mannatech Inc. (MTEx)	24.9	B
			late filer, fortress balance sheet
94	NeuroPace Inc. (NPCE)	25.1	B
95	Zoetis Inc. (ZTS) <	25.4	B
96	Mirum Pharmaceuticals, Inc. (MIRM)	25.7	B
97	Phibro Animal Health Corp. (PAHC)	25.9	B
98	GE HealthCare Technologies Inc. (GEHC)	26.2	B
99	Sensus Healthcare, Inc. (SRTS)	26.5	B
100	Lineage Cell Therapeutics, Inc. (LCTX)	26.8	B

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(46.3%)	8.0%	16
Distance from 52-week high	(50.5%)	(31.4%)	26
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	7.6%	(1.0%)	88
Book value to price	0.10	0.28	26
Sales to price	0.31	0.31	50
Composite equity issuance, five years	(19.9%)	20.3%	8
Relative strength against the sector, log excess return	(0.83)	(0.14)	16

Diagnostics

not in the grade

Measure	Value
Piotroski F-score 8 of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	pass
Gross margin improved	pass
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	\$1.5B
Operating cash flow, four quarters	\$2.8B
Months of runway	not finite
Days since last periodic filing	64 (10-Q received Aug 6, 2026)
Median daily dollar volume, 63 sessions	\$369.6M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:Revenues	\$9.5B	2025-12-31	2026-02-12	10-K	0001555280-26-000011
2	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$2.7B	2025-12-31	2026-02-12	10-K	0001555280-26-000011
3	assets	us-gaap:Assets	\$15.5B	2025-12-31	2026-02-12	10-K	0001555280-26-000011
4	net income	us-gaap:NetIncomeLoss	\$2.7B	2025-12-31	2026-02-12	10-K	0001555280-26-000011
5	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$2.9B	2025-12-31	2026-02-12	10-K	0001555280-26-000011
6	assets	us-gaap:Assets	\$14.2B	2024-12-31	2026-02-12	10-K	0001555280-26-000011
7	revenue	us-gaap:Revenues	\$9.3B	2024-12-31	2026-02-12	10-K	0001555280-26-000011
8	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$2.7B	2024-12-31	2026-02-12	10-K	0001555280-26-000011
9	revenue	us-gaap:Revenues	\$8.5B	2023-12-31	2026-02-12	10-K	0001555280-26-000011
10	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$2.6B	2023-12-31	2026-02-12	10-K	0001555280-26-000011

11	revenue	us-gaap:Revenues	\$8.1B	2022-12-31	2025-02-13	10-K	0001555280-25-000102
12	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$2.5B	2022-12-31	2025-02-13	10-K	0001555280-25-000102
13	revenue	us-gaap:Revenues	\$7.8B	2021-12-31	2024-02-13	10-K	0001555280-24-000143
14	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$2.3B	2021-12-31	2024-02-13	10-K	0001555280-24-000143
15	current assets	us-gaap:AssetsCurrent	\$6.8B	2025-12-31	2026-02-12	10-K	0001555280-26-000011
16	current liabilities	us-gaap:LiabilitiesCurrent	\$2.2B	2025-12-31	2026-02-12	10-K	0001555280-26-000011
17	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$621.0M	2025-12-31	2026-02-12	10-K	0001555280-26-000011
18	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$3.0B	2024-12-31	2026-02-12	10-K	0001555280-26-000011
19	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$655.0M	2024-12-31	2026-02-12	10-K	0001555280-26-000011
20	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$2.4B	2023-12-31	2026-02-12	10-K	0001555280-26-000011
21	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$732.0M	2023-12-31	2026-02-12	10-K	0001555280-26-000011
22	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$1.9B	2022-12-31	2025-02-13	10-K	0001555280-25-000102
23	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$586.0M	2022-12-31	2025-02-13	10-K	0001555280-25-000102
24	assets	us-gaap:Assets	\$14.3B	2023-12-31	2025-02-13	10-K	0001555280-25-000102
25	assets	us-gaap:Assets	\$14.9B	2022-12-31	2024-02-13	10-K	0001555280-24-000143
26	shares outstanding	dei:EntityCommonStockSharesOutstanding	422,127,709	2026-02-06	2026-02-12	10-K	0001555280-26-000011
27	shares outstanding	dei:EntityCommonStockSharesOutstanding	447,791,917	2025-02-07	2025-02-13	10-K	0001555280-25-000102